Providing providers with relevant data on quality of care and profitability allows them to adjust their practices efficiently, said Erich Mounce, chief operating officer, OneOncology.
Providing providers with relevant data on quality of care and profitability allows them to adjust their practices efficiently, said Erich Mounce, chief operating officer, OneOncology.
Transcript
If a practice isn’t doing well on cost savings or achieving high-quality care, how does OneOncology approach adjusting provider practices?
Well, I think the beauty of OneOncology is it’s not this cookbook process. It’s not—here’s our only way to do it and if you don’t do it this way, we come hit you with a club. I think it’s a variation of themes. We’ve got some practices—they’re really restrict regimens. We have some practices that have a little bit more selection of preferred regimens. It’s an education process and a rapid learning cycle of how that data is recirculated back. So, the first thing we do is sort of measure where they are and then start to feedback data. Then we also show them if they would adhere a little bit more to this pathway or perform a little bit better under this contract, look how that will affect either your compensation or profitability. So, it’s really taking all of that data, and constantly feeding back accurately and allowing the doctors to buy into that. That really does tend to move physician behavior a lot more than us just saying; you guys aren’t doing well—you need to do it this way.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More